6051 Balancing pros and cons of the addition of Bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials exploring absolute benefits

✍ Scribed by Cuppone, F.; Vaccaro, V.; Loupakis, F.; Milella, M.; Carlini, P.; Nisticò, C.; Falcone, A.; Giannarelli, D.; Cognetti, F.; Bria, E.

• Book ID: 122861430
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 67 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/S1359-6349(09)71146-2